963 / 1578
SBRT for cholangiocarcinoma
Author
Patients
Prim//mets
Dose-fractionation
(prescript. isodose)
Median
follow-up
(m)
TTP
Median (m)
Survival (%)
1 year
Tse 2008
10 IHC 6 x 6-9 Gy (100%)
18
-
60
Kopek 2010
27
26 KT/1 IHC
3 x 15Gy (67%)
64
7
45
Polistina 2011 10 KT
3 x 10 Gy (80%)
+ weekly
gemcitabine
36
30
80
Ibarra 2012
11 IHC
3 x 7.5-11.5
8
-
75